Compass Pathways Targeting “Patient Access” to Synthetic Psilocybin Compass Pathways is a life sciences company, founded in 2016, to “accelerate patient access to evidence-based innovation in mental health.” According to their …
The psilocybin field is underdeveloped. Only one active ingredient in “magic mushrooms” has been formulated and studied in a meaningful way.
The pharmaceutical industry has failed to create safe and effective chemical compositions for treating mood disorders, such as depression, anxiety, compulsion, addiction, etc.
The psilocybin field needs to shift its focus from “magic mushrooms” to the active molecules within them.
We can make better products for treating mood disorders by formulating naturally occurring psilocybin derivatives.